{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:34:42Z","timestamp":1788813282775,"version":"build-2803163510"},"reference-count":61,"publisher":"BMJ","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2013,3,7]]},"published-print":{"date-parts":[[2013]]},"abstract":"\n Objective<\/jats:title>\n To assess whether three novel interventions, formulated based on a systems medicine therapeutic concept, reduced disease activity in patients with relapsing\u2013remitting multiple sclerosis (MS) who were either treated or not with disease-modifying treatment.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n A 30-month randomised, double-blind, placebo-controlled, parallel design, phase II proof-of-concept clinical study.<\/jats:p>\n <\/jats:sec>\n \n Settings<\/jats:title>\n Cyprus Institute of Neurology and Genetics.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n 80 participants were randomised into four groups of 20 each. A total of 41 (51%) patients completed the 30-month trial. The eligibility criteria were an age of 18\u201365; a diagnosis of relapsing\u2013remitting MS according to the McDonald criteria; a score of 0.0\u20135.5 on the Expanded Disability Status Scale (EDSS); MRI showing lesions consistent with MS; at least one documented clinical relapse and either receiving or not a disease-modifying treatment within the 24-month period before enrolment in the study. Patients were excluded because of a recent (<30\u2005days) relapse, prior immunosuppressant or monoclonal antibody therapy, pregnancy or nursing, other severe disease compromising organ function, progressive MS, history of recent drug or alcohol abuse, use of any additional food supplements, vitamins or any form of polyunsaturated fatty acids, and a history of severe allergic or anaphylactic reactions or known specific nutritional hypersensitivity.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n The first intervention (A) was composed of \u03a9-3 and \u03a9-6 polyunsaturated fatty acids at 1:1 wt\/wt. Specifically, the \u03a9-3 fatty acids were docosahexaenoic acid and eicosapentaenoic acid at 3:1 wt\/wt, and the \u03a9-6 fatty acids were linoleic acid and \u03b3-linolenic acid at 2:1 wt\/wt. This intervention also included minor quantities of other specific polyunsaturated, monounsaturated and saturated fatty acids as well as vitamin A and vitamin E (\u03b1-tocopherol). The second intervention (B, PLP10) was a combination of A and \u03b3-tocopherol. The third intervention (C) was \u03b3-tocopherol alone. The fourth group of 20 participants received placebo. The interventions were administered per os (by mouth) once daily, 30\u2005min before dinner for 30\u2005months.<\/jats:p>\n <\/jats:sec>\n \n Main outcome measures<\/jats:title>\n The primary end point was the annualised relapse rate (ARR) of the three interventions versus the placebo at 2\u2005years. The secondary end point was the time to confirmed disability progression at 2\u2005years.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 41 (51%) patients completed the 30-month trial. Overall, for the per-protocol analysis of the 2-year primary end point, eight relapses were recorded in the PLP10 group (n=10; 0.40 ARR) versus 25 relapses in the placebo group (n=12; 1.04 ARR), representing a 64% adjusted relative rate reduction for the PLP10 group (RRR 0.36, 95% CI 0.15 to 0.87, p=0.024). In a subgroup analysis that excluded patients on monoclonal antibody (natalizumab) treatment, the observed adjusted RRR became stronger (72%) over the 2\u2005years (RRR 0.28, 95% CI 0.10 to 0.79, p=0.016). The per-protocol analysis for the secondary outcome at 2\u2005years, the time to disability progression, was significantly longer only for PLP10. The cumulative probability of disability progression at 2\u2005years was 10% in the PLP10 group and 58% in the placebo group (unadjusted log-rank p=0.019). In a subgroup analysis that excluded patients on natalizumab, the cumulative probability of progression was 10% for the 10 patients in the PLP10 group and 70% for the 12 patients in the placebo group, representing a relative 86% decrease in the risk of the sustained progression of disability in the PLP10 group (unadjusted log-rank p=0.006; adjusted HR, 0.11; 95% CI 0.01 to 0.97, p=0.047). No adverse events were reported. Interventions A (10 patients) and C (9 patients) showed no significant efficacy.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In this small proof-of-concept, randomised, double-blind clinical trial; the PLP10 treatment significantly reduced the ARR and the risk of sustained disability progression without any reported serious adverse events. Larger studies are needed to further assess the safety and efficacy of PLP10.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n \n International Standard Randomised Controlled Trial, number\n ISRCTN87818535<\/jats:ext-link>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/bmjopen-2012-002170","type":"journal-article","created":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T20:20:09Z","timestamp":1366316409000},"page":"e002170","source":"Crossref","is-referenced-by-count":56,"title":["A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial"],"prefix":"10.1136","volume":"3","clinical-trial-number":[{"clinical-trial-number":"isrctn87818535","registry":"10.18810\/isrctn"}],"author":[{"given":"Marios C","family":"Pantzaris","sequence":"first","affiliation":[{"name":"The Cyprus Institute of Neurology and Genetics (CING) Neurology Clinic C and PALUPA Medical Ltd, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N","family":"Loukaides","sequence":"additional","affiliation":[{"name":"The Cyprus Institute of Neurology and Genetics (CING) Neurology Clinic C and PALUPA Medical Ltd, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia E","family":"Ntzani","sequence":"additional","affiliation":[{"name":"Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine (UISM), Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis S","family":"Patrikios","sequence":"additional","affiliation":[{"name":"The Cyprus Institute of Neurology and Genetics (CING) Neurology Clinic C and PALUPA Medical Ltd, Nicosia, Cyprus"},{"name":"Department of Health and Science, European University Cyprus, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2013,4,17]]},"reference":[{"key":"2025121408301348000_3.4.e002170.1","first-page":"201","article-title":"New insights into the genetics of multiple sclerosis","volume":"39","author":"Baranzini","year":"2002","journal-title":"J Rehabil Res Dev"},{"key":"2025121408301348000_3.4.e002170.2","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-2-52"},{"key":"2025121408301348000_3.4.e002170.3","unstructured":"Lobo I. Multifactorial inheritance and genetic disease. Nat Educ 2008;1(1) http:\/\/www.nature.com\/scitable\/topicpage\/multifactorial-inheritance-and-genetic-disease-919."},{"key":"2025121408301348000_3.4.e002170.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08220-X"},{"key":"2025121408301348000_3.4.e002170.5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/oxfordjournals.bmb.a072632","article-title":"Free radicals in brain metabolism and pathology","volume":"49","author":"Evans","year":"1993","journal-title":"Br Med Bull"},{"key":"2025121408301348000_3.4.e002170.6","first-page":"11","article-title":"Reactive oxygen species and the neurodegenerative disorders","volume":"27","author":"Knight","year":"1997","journal-title":"Ann Clin Lab Sci"},{"key":"2025121408301348000_3.4.e002170.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(00)01746-X"},{"key":"2025121408301348000_3.4.e002170.8","doi-asserted-by":"publisher","DOI":"10.1097\/00019052-200306000-00003"},{"key":"2025121408301348000_3.4.e002170.9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1750-3639.1999.tb00212.x","article-title":"Demyelination: the role of reactive oxygen and nitrogen species","volume":"9","author":"Smith","year":"1999","journal-title":"Brain Pathol"},{"key":"2025121408301348000_3.4.e002170.10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030209"},{"key":"2025121408301348000_3.4.e002170.11","doi-asserted-by":"publisher","DOI":"10.1186\/gm2"},{"key":"2025121408301348000_3.4.e002170.12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejcn.1602255"},{"key":"2025121408301348000_3.4.e002170.13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/ajcn\/50.4.801","article-title":"Essential fatty acid and lipid profiles in plasma and erythrocytes in patients with multiple sclerosis","volume":"50","author":"Cunnane","year":"1989","journal-title":"Am J Clin Nutr"},{"key":"2025121408301348000_3.4.e002170.14","doi-asserted-by":"crossref","unstructured":"Harbige LS, Pinto E, Xiang M, et al. Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis. Proc Nutr Soc 2008;67:E21.","DOI":"10.1017\/S0029665108006307"},{"key":"2025121408301348000_3.4.e002170.15","doi-asserted-by":"publisher","DOI":"10.1007\/BF02544017"},{"key":"2025121408301348000_3.4.e002170.16","doi-asserted-by":"crossref","first-page":"S1505","DOI":"10.1093\/ajcn\/83.6.1505S","article-title":"n\u22123 Polyunsaturated fatty acids, inflammation, and inflammatory diseases","volume":"83","author":"Calder","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"2025121408301348000_3.4.e002170.17","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.4049\/jimmunol.152.7.3578","article-title":"Involvement of the cystine transport system xc- in the macrophage-induced glutamate-dependent cytotoxicity to neurons","volume":"152","author":"Piani","year":"1994","journal-title":"J Immunol"},{"key":"2025121408301348000_3.4.e002170.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0736-5748(00)00013-7"},{"key":"2025121408301348000_3.4.e002170.19","doi-asserted-by":"publisher","DOI":"10.1079\/PNS2002166"},{"key":"2025121408301348000_3.4.e002170.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0753-3322(02)00256-1"},{"key":"2025121408301348000_3.4.e002170.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2007.02.007"},{"key":"2025121408301348000_3.4.e002170.22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.6.3912"},{"key":"2025121408301348000_3.4.e002170.23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2174\/156652409788488748","article-title":"Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer","volume":"9","author":"Janakiram","year":"2009","journal-title":"Curr Mol Med"},{"key":"2025121408301348000_3.4.e002170.24","doi-asserted-by":"publisher","DOI":"10.1007\/s11745-004-1339-7"},{"key":"2025121408301348000_3.4.e002170.25","doi-asserted-by":"publisher","DOI":"10.1038\/nri2294"},{"key":"2025121408301348000_3.4.e002170.26","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/jlb.62.4.438","article-title":"Oral administration of unsaturated fatty acids: effects on human peripheral blood T lymphocyte proliferation","volume":"62","author":"Rossetti","year":"1997","journal-title":"J Leukoc Biol"},{"issue":"Suppl 1","key":"2025121408301348000_3.4.e002170.27","first-page":"S25","article-title":"Vitamin E and other endogenous antioxidants in the central nervous system","volume":"53","author":"Vatassery","year":"1998","journal-title":"Geriatrics"},{"key":"2025121408301348000_3.4.e002170.28","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(83)90290-4"},{"key":"2025121408301348000_3.4.e002170.29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.7.3217"},{"key":"2025121408301348000_3.4.e002170.30","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/ajcn\/76.4.703","article-title":"The European perspective on vitamin E: current knowledge and future research","volume":"76","author":"Brigelius-Floh\u00e9","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"2025121408301348000_3.4.e002170.31","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/mnfr.200700289","article-title":"Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases Mol","volume":"52","author":"Calder","year":"2008","journal-title":"Nutr Food Res"},{"key":"2025121408301348000_3.4.e002170.32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2008\/358052","article-title":"Omega-3 fatty acids and PPAR\u03b3 in cancer","volume":"2008","author":"Edwards","year":"2008","journal-title":"PPAR Res"},{"key":"2025121408301348000_3.4.e002170.33","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.367"},{"key":"2025121408301348000_3.4.e002170.34","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2335"},{"key":"2025121408301348000_3.4.e002170.35","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.22390"},{"key":"2025121408301348000_3.4.e002170.36","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.21537"},{"key":"2025121408301348000_3.4.e002170.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2005.02.001"},{"key":"2025121408301348000_3.4.e002170.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91118-5"},{"key":"2025121408301348000_3.4.e002170.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(01)00101-1"},{"key":"2025121408301348000_3.4.e002170.40","doi-asserted-by":"publisher","DOI":"10.1079\/PNS2002174"},{"key":"2025121408301348000_3.4.e002170.41","doi-asserted-by":"publisher","DOI":"10.1054\/plef.2001.0283"},{"key":"2025121408301348000_3.4.e002170.42","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1007\/BF02562295","article-title":"The effect of eicosapentanoic acid on matrix metalloproteinase gene expression","volume":"34","author":"McCabe","year":"1999","journal-title":"Lipids"},{"key":"2025121408301348000_3.4.e002170.43","doi-asserted-by":"crossref","unstructured":"Shinto L, Marracci G, Bumgarner L, et al. The effects of Omega-3 fatty acids on matrix metalloproteinase-9 production and cell migration in human immune cells: implications for multiple sclerosis. Autoimmune Dis 2011;2011:1\u20136.","DOI":"10.4061\/2011\/134592"},{"key":"2025121408301348000_3.4.e002170.44","doi-asserted-by":"publisher","DOI":"10.3945\/jn.109.113233"},{"key":"2025121408301348000_3.4.e002170.45","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm223"},{"key":"2025121408301348000_3.4.e002170.46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0005-2760(93)90049-F","article-title":"Changes of n\u20143 and n\u20146 fatty acids in plasma and circulating cells of normal subjects, after prolonged administration of 20:5 (EPA) and 22:6 (DHA) ethyl esters and prolonged washout","volume":"1210","author":"Marangoni","year":"1993","journal-title":"Biochim Biophy Acta"},{"key":"2025121408301348000_3.4.e002170.47","doi-asserted-by":"crossref","first-page":"376S","DOI":"10.1093\/ajcn\/71.1.376S","article-title":"Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders1","volume":"71","author":"Mart\u00ednez","year":"2000","journal-title":"Am J Clin Nutr"},{"key":"2025121408301348000_3.4.e002170.48","unstructured":"Committee for medicinal products for human use. Guideline on clinical trials in small populations European Medicines Agency, London, UK, 2006;1\u201310."},{"key":"2025121408301348000_3.4.e002170.49","unstructured":"Dallal GE. The Little Handbook of Statistical Practice ebook (kindle edition). USA, 2008."},{"key":"2025121408301348000_3.4.e002170.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2009.07.017"},{"key":"2025121408301348000_3.4.e002170.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2011.06.006"},{"key":"2025121408301348000_3.4.e002170.52","doi-asserted-by":"crossref","unstructured":"Farinotti M Simi S Di Pietrantonj C . Dietary interventions for multiple sclerosis (Review). Cochrane Database Syst Rev 2007(1)CD004192.","DOI":"10.1002\/14651858.CD004192.pub2"},{"key":"2025121408301348000_3.4.e002170.53","first-page":"175","article-title":"Multiple sclerosis review","volume":"37","author":"Marvin","year":"2012","journal-title":"P T"},{"key":"2025121408301348000_3.4.e002170.54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"2025121408301348000_3.4.e002170.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494"},{"key":"2025121408301348000_3.4.e002170.56","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/ncpneuro1009","article-title":"Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis","volume":"5","author":"Mehta","year":"2009","journal-title":"Nat Clin Pract Neurol"},{"key":"2025121408301348000_3.4.e002170.57","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2174\/1389557043403431","article-title":"Omega 3-fatty acids: health benefits and cellular mechanisms of action","volume":"4","author":"Rafat","year":"2004","journal-title":"Mini Rev Med Chem"},{"key":"2025121408301348000_3.4.e002170.58","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/ajcn\/84.6.1277","article-title":"Polyunsaturated fatty acids, membrane organization, T cells, and antigen presentation","volume":"84","author":"Shaikh","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"2025121408301348000_3.4.e002170.59","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0005-2760(82)90282-X","article-title":"Increased polyunsaturated fatty acids in developing and regenerating peripheral nerve","volume":"712","author":"Yao","year":"1982","journal-title":"Biochim Biophy Acta"},{"key":"2025121408301348000_3.4.e002170.60","doi-asserted-by":"publisher","DOI":"10.1042\/bj1640323"},{"key":"2025121408301348000_3.4.e002170.61","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/BF00964414","article-title":"Turnover rate of molecular species of sphingomyelin in rat brain","volume":"6","author":"LeBaron","year":"1981","journal-title":"Neurochem Res"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2012-002170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:30:20Z","timestamp":1765729820000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2012-002170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":61,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,4,17]]},"published-print":{"date-parts":[[2013]]}},"alternative-id":["10.1136\/bmjopen-2012-002170"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2012-002170","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}